For Infectious Disease Sciences (IDS) researchers combatting infections in immunocompromised people is a central focus, since these individuals are disproportionately affected by infectious disease. IDS physicians and scientists leverage laboratory, clinical and computational methods to advance our understanding of epidemiology and host-pathogen interactions, and to develop new tools for diagnosing, preventing, treating, and curing infections.
Our physicians and scientists apply their extensive experience in immunocompetent and immunocompromised populations to study the epidemiology of infectious diseases, investigate emerging infectious diseases, develop novel diagnostic methods and perform clinical trials for new treatments for major infections. Specific areas of research include:
IDS researchers are playing a key role in the development of new COVID-19 prevention and treatment strategies. Our researchers are heading up several population-based studies as well as leading the way in clinical response to the virus.
Dr. Michael Boeckh works on detection, prevention, treatment, and identifying biomarkers for disease severity of herpesviruses (primarily cytomegalovirus and human herpesvirus-6) and respiratory viruses in transplant recipients and patients with sepsis.
Dr. Joshua Hill studies the epidemiology of infections in immunocompromised populations, with a focus on improving preventative and treatment strategies for infections (primarily human herpesvirus-6 and other viral infections).
Dr. Keith Jerome, as the Director of the University of Washington Virology Laboratory, leads design and implementation of molecular testing assays for a full range of human viruses.
Dr. Catherine Liu is working to optimize the use of antimicrobials and infectious disease diagnostics to improve quality, safety and clinical outcomes and prevent the emergence and spread of antimicrobial resistant pathogens among immunocompromised patients.
Dr. Steven Pergam is working to prevent infections in immunocompromised populations (including developing new infection control strategies and educational programs), investigating risk factors for healthcare and community-acquired infections, and understanding the risks of drug resistance and healthcare-associated infections in these patient populations.
Dr. Warren Phipps is focused on the identification of bacterial causes of infection and optimal use of antimicrobials among cancer patients in sub-Saharan Africa.
Dr. Joshua Schiffer uses mathematical models to generate novel hypotheses and address clinically important questions about viral infections in immunocompromised and immunocompetent patients.
Dr. Alpana Waghmare works on the treatment and prevention of infectious diseases, (primarily respiratory infections including human rhinovirus), and on the identification of viral and host factors as potential disease severity biomarkers.
Dr. Anna Wald conducts clinical research on the natural history of viral infections and designs clinical trials of antiviral therapeutics and vaccines for viral pathogens.
Dr. Larry Corey is investigating how tissue resident cells in the genital tract contribute to host containment of herpes simplex virus (HSV)-2, with the goal of developing therapies that control HSV-2 reactivation and reduce transmission.
Dr. Joshua Schiffer uses mathematical models to inform the design and implementation of clinical and laboratory experiments about tissue-resident T cells and their role in controlling viral infections.
Dr. Anna Wald studies the epidemiology and natural history of chronic viral infections in immunocompetent and immunocompromised hosts.
Dr. Jia Zhu is investigating the human immune response to HSV-2 reactivation, including immune correlates of disease outcome, tissue-resident memory T-cell function and regulation, and mechanisms driving peripheral nerve regeneration. She is also developing a skin-on-chip microfluidic device for modeling HSV infection.
Dr. David Fredricks is identifying specific microbial communities associated with disease states including graft-vs.-host disease and bacterial vaginosis.
Dr. Christopher Johnston designs new genetic engineering approaches to uncover how bacteria (with a focus on human microbiota) behave during infection, contribute to diseases such as cancer, and acquire antibiotic resistance.
Dr. Anna Wald conducts studies to address the interaction between sexually transmitted infections and the microbiome.
Dr. Larry Corey is using adoptive transfer of genetically engineered T cells to traffic to and be effectors in lymphoid follicles with a goal to eradicate HIV infections.
Dr. Joshua Hill is studying infectious complications of CAR-T cell immunotherapies, the effects of CAR-T cell therapy on immunity to infections, and vaccine responsiveness after CAR-T cell therapy.
Dr. Keith Jerome is investigating the use of gene editing enzymes and other gene therapy approaches to target persistent viral infections including HIV, hepatitis B virus, and HSV.
Dr. Hans-Peter Kiem conducts cell and gene therapy with a focus on the biology of blood and marrow stem cells and the development of novel gene therapy and genome editing technologies for applications relevant to genetic, infectious, and malignant diseases.
Dr. Josh Schiffer is using mathematical models to develop new hypotheses and inform the design and implementation of clinical and laboratory experiments in the field of HIV cure.
Dr. Manoj Menon is enhancing cancer diagnostics in Uganda and improving the care of patients with cancer in resource-limited regions.
Dr. Warren Phipps is investigating HIV-Associated malignancies, including HHV-8 virology and the pathogenesis of Kaposi sarcoma (KS), among the most common HIV-associated malignancies worldwide.